Meanwhile, Tamura et al. showed that trastuzumab accumulates in BCBMs by using 64Cu-DOTA-trastuzumab with positron emission tomography (PET) imaging to visualize and quantify HER2-positive lesions in patients with HER2-positive breast cancer [88]. This evidence concerns the gene ERBB2 and breast carcinoma.